Therefore, there is little concern that treatment with SGLT2 inhibitors in overweight or obese diabetics with insulin resistance would further deteriorate endothelial function through the mechanism of selective insulin resistance in endothelial cells. The gene discussed is SLC5A2; the disease is diabetes mellitus.